Wednesday, June 25, 2025
  • Login
CEO North America
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel
No Result
View All Result
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel
No Result
View All Result
CEO North America
No Result
View All Result

CEO North America > News > Pfizer agrees to $5.4 billion deal for Global Blood Therapeutics

Pfizer agrees to $5.4 billion deal for Global Blood Therapeutics

in News
Pfizer agrees to $5.4 billion deal for Global Blood Therapeutics
Share on LinkedinShare on WhatsApp

Pfizer is buying blood disorder drugmaker Global Blood Therapeutics for $5.4 billion, in the latest acquisitions by the New York City based company.

Pfizer said on Monday it will pay $68.50 per share, representing a premium of 7.3% to Global Blood stock’s Friday closing and a 42.7% premium to Thursday’s closing.

The pharma company’s strong rise in sales after launching its Covid vaccine (developed with BioNTech), was eclipsed last year with lower sales. Now, with a pile of cash, the pharmaceutical company is moving forward with more acquisitions.

Last May, Pfizer purchased migraine drug maker Biohaven Pharmaceutical Holding for $11.6 billion and recently it spent an additional $6.7 billion to buy Arena Pharmaceuticals.

With Global Blood Therapeutics, Pfizer will boost its rare disease treatment business with Oxbryta, a drug first approved in 2019 to treat sickle cell disease among patients aged 12 years or older. The oral drug brought $55.2 million in sales for the company in the first quarter of 2022.

Sickle cell, an inherited blood disorder that affects about 100,000 people in the U.S.

Shares of Global Blood rose 4.5% following the deal announcement.

Tags: Global Blood TherapeuticsPfizer

Related Posts

Bessent says SALT deal will happen within 48 Hours
News

Bessent says SALT deal will happen within 48 Hours

Fund Managers Expect Quarter Point Rate Hike from Fed
News

The Fed unlikely to issue July rate cut

FedEx raises rates 6.9% for 2023, outlines cost cuts
News

FedEx beats Q4 estimates, announces new cost cuts

Marathon Oil settles for $241.5 million over air quality violations
News

Oil prices plummet below pre-Iran-Israel conflict levels

Nvidia reveals new H200 chip for AI training
News

Jensen Huang kicks off Nvidia stock offload plan

Iberdrola seeks U.S. expansion, appoints Pedro Azagra as new CEO
News

Iberdrola seeks U.S. expansion, appoints Pedro Azagra as new CEO

Antonio Filosa takes over as CEO of Stellantis
News

Antonio Filosa takes over as CEO of Stellantis

Kroger to pay $1.2 billion in opioid settlement
News

Kroger to close up to 60 stores

Hormel Foods announces leadership changes, Jeffrey Ettinger returns as interim CEO
News

Hormel Foods announces leadership changes, Jeffrey Ettinger returns as interim CEO

Musk’s AI startup now valued at $24B
News

Musk’s xAI investors face deadline

No Result
View All Result

Recent Posts

  • Ambarella shares soar more than 20% on report chip designer is exploring sale
  • U.S. Economic Confidence Slightly Improved, Still Negative
  • Bessent says SALT deal will happen within 48 Hours
  • The Fed unlikely to issue July rate cut
  • FedEx beats Q4 estimates, announces new cost cuts

Archives

Categories

  • Art & Culture
  • Business
  • CEO Interviews
  • CEO Life
  • Editor´s Choice
  • Entrepreneur
  • Environment
  • Food
  • Health
  • Highlights
  • Industry
  • Innovation
  • Issues
  • Management & Leadership
  • News
  • Opinion
  • PrimeZone
  • Printed Version
  • Technology
  • Travel
  • Uncategorized

Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org

  • CONTACT
  • GENERAL ENQUIRIES
  • ADVERTISING
  • MEDIA KIT
  • DIRECTORY
  • TERMS AND CONDITIONS

Advertising –
advertising@ceo-na.com

110 Wall St.,
3rd Floor
New York, NY.
10005
USA
+1 212 432 5800

Avenida Chapultepec 480,
Floor 11
Mexico City
06700
MEXICO

  • News
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life

  • CONTACT
  • GENERAL ENQUIRIES
  • ADVERTISING
  • MEDIA KIT
  • DIRECTORY
  • TERMS AND CONDITIONS

Advertising –
advertising@ceo-na.com

110 Wall St.,
3rd Floor
New York, NY.
10005
USA
+1 212 432 5800

Avenida Chapultepec 480,
Floor 11
Mexico City
06700
MEXICO

CEO North America © 2024 - Sitemap

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel

© 2025 JNews - Premium WordPress news & magazine theme by Jegtheme.